C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation. [PDF]
Heidenreich K+8 more
europepmc +1 more source
Correction: A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. [PDF]
Jensen RK+7 more
europepmc +1 more source
Effect of membrane phospholipids on activation of the alternative complement pathway. [PDF]
Carolyn Mold
openalex +1 more source
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley +1 more source
Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro. [PDF]
Ter Avest M+6 more
europepmc +1 more source
The potential role of complement alternative pathway activation in hypertensive renal damage. [PDF]
Wang C, Wang Z, Zhang W.
europepmc +1 more source
Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells. [PDF]
Claude Lambré+3 more
openalex +1 more source
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková+14 more
wiley +1 more source